News FDA okays Italfarmaco’s non-steroidal DMD therapy Duvyzat Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face